Metraipolis › archive › dc_a982f7bc311e

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study — Europe PMC PMID:41494164

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41494164
DOI
10.2196/68101
License (as archived)
solo-consultazione
Archived
2026-11-07T00:58:55.045Z
SHA-256 of the archived text
9f003070b7231f9da1c9ae95d923171e76d4596fa8e552dc21a699eff415ee81
Stable URL of this page
https://metraipolis.com/documento/dc_a982f7bc311e

How to cite

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study — Europe PMC PMID:41494164 — Europe PMC (en), https://europepmc.org/article/MED/41494164 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a982f7bc311e (Metraipolis archive dc_a982f7bc311e, sha256 9f003070b7231f9da1c9ae95d923171e76d4596fa8e552dc21a699eff415ee81)
BibTeX
@misc{dca982f7bc311e,
  title = {Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study — Europe PMC PMID:41494164},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41494164},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a982f7bc311e; sha256 9f003070b7231f9da1c9ae95d923171e76d4596fa8e552dc21a699eff415ee81},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41494164. Agents can read the archived copy with the MCP tool read_document.